Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva/Ivax finalized

This article was originally published in The Tan Sheet

Executive Summary

FTC has approved the final consent order related to Teva Pharmaceuticals' acquisition of fellow generics firm Ivax following an open public comment period, the commission announces March 7. The acquisition was completed Jan. 26 (1"The Tan Sheet" Jan. 30, 2006, In Brief)...

You may also be interested in...

Teva acquires Ivax

Teva has completed the acquisition of generics firm Ivax Jan. 26, the Israeli firm announces in a same-day release. The deal increases Teva's OTC distribution and private label OTC portfolio (1"The Tan Sheet" Aug. 1, 2005, p. 11). To preserve competition, FTC requires that Teva divest all of the rights and assets related to 15 of the firms' prescription generics. The rights and assets to be divested will be divided between Barr Pharmaceuticals and Par Pharmaceuticals. Teva and Ivax are required to provide transitional services to Barr and Par until the firms receive FDA approval to manufacture the drugs themselves. The order will be open to public comment until Feb. 21, 2006. FTC will decide whether to make the order final following the close of the public comment period...

US FDA Connects Dots For Drug Manufacturers’ Responses To CRLs With Draft Guidance

CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.

Inovio COVID-19 Vaccine Trial Delayed By FDA Partial Hold

The US FDA appears to have concerns about the device used to administer the vaccine.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts